Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity.
Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJ, Petter M, Chesson JM, Langer C, Warimwe GM, Duffy MF, Rogerson SJ, Bull PC, Cowman AF, Marsh K, Beeson JG
Perspectives: The missing pieces.
Crabb BS, Beeson JG, Amino R, Ménard R, Waters A, Winzeler EA, Wahlgren M, Fidock DA, Nwaka S
Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial.
Senn N, Rarau P, Stanisic DI, Robinson L, Barnadas C, Manong D, Salib M, Iga J, Tarongka N, Ley S, Rosanas-Urgell A, Aponte JJ, Zimmerman PA, Beeson JG, Schofield L, Siba P, Rogerson SJ, Reeder JC, Mueller I
High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria.
Reddy SB, Anders RF, Beeson JG, Färnert A, Kironde F, Berenzon SK, Wahlgren M, Linse S, Persson KE
Antibody to P. falciparum in pregnancy varies with intermittent preventive treatment regime and bed net use.
Aitken EH, Mbewe B, Luntamo M, Kulmala T, Beeson JG, Ashorn P, Rogerson SJ
Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.
Wilson DW, Fowkes FJ, Gilson PR, Elliott SR, Tavul L, Michon P, Dabod E, Siba PM, Mueller I, Crabb BS, Beeson JG